Transworld Health podcast

Highlights ESMO GI 2026 - EN

0:00
8:13
Retroceder 15 segundos
Avanzar 15 segundos
The purpose of this podcast is to provide continuing medical education and information for Healthcare Professionals. This content contains scientific information intended exclusively for Healthcare Professionals authorised to prescribe or dispense medicinal products or medical devices in Spain, as it requires specialised medical knowledge for its proper interpretation. Access to this content implies confirmation of your status as a Healthcare Professional. The views, experiences, and conclusions expressed are those of the individual participants. ---- ESMO GI 2026 has reinforced the role of KRAS G12D-targeted therapies as one of the most promising areas of development in pancreatic adenocarcinoma, with encouraging results in both the first-line setting and in previously treated disease. In KRAS G12D-mutated pancreatic adenocarcinoma, two phase I studies were presented. The first evaluated zoldonrasib in combination with chemotherapy as first-line treatment, demonstrating high objective response and disease control rates, which have supported the initiation of the phase III RASolute-305 trial. The second investigated the combination of zoldonrasib and daraxonrasib in the second- and third-line settings, reporting promising efficacy in terms of both objective response rate and progression-free survival, leading to the development of the phase III RASolute-309 trial. The GLEAM study was also presented. This trial evaluated zolbetuximab in combination with gemcitabine and nab-paclitaxel in CLDN18.2-positive tumours. The study did not demonstrate an improvement in progression-free survival or overall survival, highlighting the need for further optimisation of patient selection for this therapeutic target. In biliary tract cancers, updated data on FGFR2 inhibitors were among the most relevant findings. Both fanregratinib and the combination of futibatinib with chemotherapy and immunotherapy demonstrated meaningful clinical activity, opening new avenues for research, particularly in intrahepatic cholangiocarcinoma. Finally, the episode reviews the results of an intratumoural phosphorus-32 brachytherapy strategy for locally advanced pancreatic adenocarcinoma. Although the study was not designed for a formal comparison between treatment arms, the findings showed a favourable signal in objective response rate, progression-free survival, and overall survival, supporting the further development of confirmatory clinical trials. This episode provides a comprehensive overview of the key highlights from ESMO GI 2026 and explores how emerging targeted therapies and locoregional treatment strategies continue to expand the therapeutic landscape for hepatobiliary and pancreatic malignancies. --- The 3rd Edition of TooMore GI is also available at: transworldeditors.com/toomore-gi-3/

Otros episodios de "Transworld Health"